NikhilKhandelwalCFA

Biocon in Pharma Rally

Long
NSE:BIOCON   BIOCON LTD
Government take steps to ramp up production of Amphotericin B. A sudden increase in demand has been observed in some states for Amphotericin B which is being actively prescribed by the physicians to patients suffering from Mucormycosis, a post #COVID19 complication. @businessline

Biocon will be in focus

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.